Search research articles
Contact Us
Filters
Showing results (31-40 of 90) with videos related to
Page
of 9
Sort By:
American Journal of Hematology
|
April 15, 1999
Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II
A De Renzo, L F Santoro, R Notaro, et al.
Leukemia Research
|
April 25, 2006
Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon
M Breccia, D Diverio, F Pane, et al.
Blood
|
July 29, 1998
Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis
C Selleri, J P Maciejewski, F Pane, et al.
Leukemia
|
May 9, 2013
Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making
F Ferrara, G Barosi, A Venditti, et al.
Blood
|
September 25, 1999
BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients
F Pane, I Mostarda, C Selleri, et al.
British Journal of Haematology
|
March 1, 1996
All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukaemia followed by ATRA-induced pseudotumour cerebri
C Selleri, F Pane, R Notaro, et al.
Blood
|
October 1, 1996
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
F Pane, F Frigeri, M Sindona, et al.
Leukemia
|
November 13, 2004
Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status
G Alimena, M Breccia, M Mancini, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology
|
February 6, 2010
Fine needle aspiration cytology and flow cytometry immunophenotyping of non-Hodgkin lymphoma: can we do better?
P Zeppa, E Vigliar, I Cozzolino, et al.
The Journal of Infectious Diseases
|
July 1, 1996
Pseudouridine and 1-ribosylpyridin-4-one-3-carboxamide (PCNR) serum concentrations in human immunodeficiency virus type 1-infected patients are independent predictors for AIDS progression
M Intrieri, G Calcagno, G Oriani, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 90) with videos related to
Sort By:
Page
of 9
American Journal of Hematology
|
April 15, 1999
Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II
A De Renzo, L F Santoro, R Notaro, et al.
Leukemia Research
|
April 25, 2006
Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon
M Breccia, D Diverio, F Pane, et al.
Blood
|
July 29, 1998
Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis
C Selleri, J P Maciejewski, F Pane, et al.
Leukemia
|
May 9, 2013
Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making
F Ferrara, G Barosi, A Venditti, et al.
Blood
|
September 25, 1999
BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients
F Pane, I Mostarda, C Selleri, et al.
British Journal of Haematology
|
March 1, 1996
All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukaemia followed by ATRA-induced pseudotumour cerebri
C Selleri, F Pane, R Notaro, et al.
Blood
|
October 1, 1996
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
F Pane, F Frigeri, M Sindona, et al.
Leukemia
|
November 13, 2004
Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status
G Alimena, M Breccia, M Mancini, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology
|
February 6, 2010
Fine needle aspiration cytology and flow cytometry immunophenotyping of non-Hodgkin lymphoma: can we do better?
P Zeppa, E Vigliar, I Cozzolino, et al.
The Journal of Infectious Diseases
|
July 1, 1996
Pseudouridine and 1-ribosylpyridin-4-one-3-carboxamide (PCNR) serum concentrations in human immunodeficiency virus type 1-infected patients are independent predictors for AIDS progression
M Intrieri, G Calcagno, G Oriani, et al.
Page
of 9